10-chloro-2-cyclopentyl-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-5-one | 946825-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 嘧啶二氮卓类
• 英文名称: 10-chloro-2-cyclopentyl-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-5-one
• 英文别名: 2-chloro-9-cyclopentyl-5,7,8,9-tetrahydro-6H-pyrimido[4,5-b][1,4]diazepin-6-one；9-chloro-6-cyclopentyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one；2-chloro-9-cyclopentyl-5,7,8,9-tetrahydro-pyrimido[4,5-b][1,4]diazepin-6-one；2-chloro-9-cyclopentyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one；2-chloro-9-cyclopentyl-7,8-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6-one
• CAS: 946825-97-4
• 化学式: C₁₂H₁₅ClN₄O
• 分子量: 266.73
• InChiKey: RSRPLYCCLBLNTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  10-chloro-2-cyclopentyl-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-5-one 在 盐酸 、 caesium carbonate 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 4-[(2-cyclopentyl-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]-3-methoxy-benzoic acid
  参考文献：
  名称：

  Identification of novel, potent and selective inhibitors of Polo-like kinase 1

  摘要：

  A series of pyrimidodiazepines was identified as potent Polo-like kinase 1 (PLK1) inhibitors. The synthesis and SAR are discussed. The lead compound 7 (RO3280) has potent inhibitory activity against PLK1, good selectivity against other kinases, and excellent in vitro cellular potency. It showed strong antitumor activity in xenograft mouse models. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.052
• 作为产物：
  描述：

  3-(环戊基氨基)丙酸乙酯 在 铁粉 、 碳酸氢钠 、 溶剂黄146 作用下， 以 乙酸乙酯 为溶剂， 反应 20.0h， 生成 10-chloro-2-cyclopentyl-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-5-one
  参考文献：
  名称：

  Identification of novel, potent and selective inhibitors of Polo-like kinase 1

  摘要：

  A series of pyrimidodiazepines was identified as potent Polo-like kinase 1 (PLK1) inhibitors. The synthesis and SAR are discussed. The lead compound 7 (RO3280) has potent inhibitory activity against PLK1, good selectivity against other kinases, and excellent in vitro cellular potency. It showed strong antitumor activity in xenograft mouse models. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.052
• 作为试剂：
  描述：

  4-氨基-1-甲基哌啶 、 2,5-二氟-4-硝基苯甲酸 在 10-chloro-2-cyclopentyl-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-5-one 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以43%的产率得到2,5-difluoro-N-(1-methyl-4-piperidyl)-4-nitro-benzamide
  参考文献：
  名称：

  NOVEL COMPOUNDS

  摘要：

  提供了一个化合物的化学式(I)： 其制备方法，药物组合物以及在治疗中的用途。

  公开号：

  US20080009482A1

文献信息

• SUBSTITUTED PYRIMIDODIAZEPINES
  申请人：Chen Shaoqing

  公开号：US20080234255A1

  公开（公告）日：2008-09-25

  The present invention provides PLK1 inhibitor compounds of formula I: Useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas.

  本发明提供了公式I的PLK1抑制剂化合物： 用于治疗或控制细胞增殖性疾病，特别是肿瘤性疾病。这些化合物和含有这些化合物的配方可能在治疗或控制实体肿瘤方面有用，例如乳腺、结肠、肺和前列腺肿瘤以及其他肿瘤性疾病，如非霍奇金淋巴瘤。
• [EN] POLO-LIKE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE DE TYPE POLO
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009067547A1

  公开（公告）日：2009-05-28

  Compounds of the following formula are provided for use with kinases, wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供以下公式的化合物供激酶使用，其中变量如本文所定义。还提供包含这些化合物的药物组合物、试剂盒和制造物品；用于制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• [EN] PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE COMME INHIBITEURS DE PROTÉINE KINASES
  申请人：CYCLACEL LTD

  公开号：WO2009040556A1

  公开（公告）日：2009-04-02

  The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N-(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and R2 are each independently H, alkyl or cycloalkyl; R4 and R4' are each independently H or alkyl; or R4 and R4' together form a spiro cycloalkyl group; R19 is H, alkyl, aryl or a cycloalkyl group; R6 is OR8 or halogen; and R7 and R8 are each independently H or alkyl. Further aspects relate to pharmaceutical compositions comprising said compounds and use therefore in the treatment of proliferative disorders and the like.

  本发明涉及公式(VII)I的化合物，或其药学上可接受的盐或酯，其中：X为NR7；Y为O或N-(CH2)nR19；n为1、2或3；m为1或2；R1和R2分别独立地为H、烷基或环烷基；R4和R4'分别独立地为H或烷基；或者R4和R4'一起形成螺环烷基基团；R19为H、烷基、芳基或环烷基基团；R6为OR8或卤素；而R7和R8各自独立地为H或烷基。进一步方面涉及包括上述化合物的药物组合物以及其在治疗增殖性疾病等方面的用途。
• Dihydrodiazepines useful as inhibitors of protein kinases
  申请人：Kay David

  公开号：US20080167289A1

  公开（公告）日：2008-07-10

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及一种作为蛋白激酶抑制剂的化合物。该发明还提供包含所述化合物的药用合适组合物，并提供使用这些组合物在治疗各种疾病、状况或障碍中的方法。该发明还提供制备本发明化合物的方法。
• POLO-LIKE KINASE INHIBITORS
  申请人：Cao Sheldon X.

  公开号：US20090291938A1

  公开（公告）日：2009-11-26

  Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供了以下公式的化合物，用于与激酶一起使用：其中变量的定义如下。还提供了包含这些化合物的制药组合物、工具包和制造物品；用于制造这些化合物的方法和中间体；以及使用这些化合物的方法。